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JOURNAL OF HEPATOLOGYTo the Editor:
We thank Dr. Bitetto et al. for their interest in our study recently
published in the Journal of Hepatology [1]. In this study, we
reported a high prevalence of severe vitamin D deﬁciency in
patients with chronic hepatitis C, even in the absence of signiﬁ-
cant liver ﬁbrosis. We found that vitamin D deﬁciency was asso-
ciated with failure to achieve a sustained virologic response (SVR)
to therapy of chronic hepatitis C with pegylated interferon-alfa
and ribavirin. Bitetto et al. have now accentuated the important
question, whether vitamin D deﬁciency is caused by hepatitis C
virus (HCV) infection, or whether vitamin D deﬁciency may
confer an enhanced susceptibility to chronic HCV infection. We
believe that this question cannot be ﬁnally answered at the
moment. In our study, we reported a slight increase of
25-hydroxyvitamin D serum levels from baseline to week 24 after
completion of antiviral therapy in those patients who achieved a
SVR. As highlighted by Bitetto et al. and others [2,3], we have
made an attempt to stratify the patients included in this
sub-analysis according to the season in which serum samples
for vitamin D measurement were taken. In detail, 50% of patients
started therapy in winter/spring and SVR was ascertained in
summer/autumn, which was vice versa in the remaining 50% of
patients. Meanwhile, we have also re-analyzed our complete
cohort according to the season when baseline serum samples
for vitamin D detection were taken. Although we observed
slightly lower baseline 25-hydroxyvitamin D serum levels in
patients who started therapy in winter/spring compared to sum-
mer/autumn (mean 16.6 and 18.7 ng/ml, p = 0.054), severe vita-
min D deﬁciency (<10 ng/ml) was associated with chronic HCV
infection during all seasons (26% vs. 19% in winter/spring vs. sum-
mer/autumn, respectively, compared to 20% vs. 6% in winter/
spring vs. summer/autumn samples in our non-HCV infected con-
trol group). In addition, season had no signiﬁcant inﬂuence on
SVR rates. Nevertheless, we fully agree with Bitetto et al. that
our observations do not prove that HCV infection itself can cause
vitamin D deﬁciency. In addition to a residual season inﬂuence,
factors such as changes in life-style or eating habits may contrib-Tips for portal vein thrombosi
unblockin
To the Editor:
Han et al. recently published a case series of patients with cirrhosis
whohaddevelopedportalandsplanchnicvein thrombosis atvarious
intervals from treatment with transjugular intrahepatic portosys-
Journal of Hepatology 20ute to the increase of vitamin D serum levels after successful HCV
eradication. To resolve the ‘‘what comes ﬁrst’’ question results of
basic research on a potential interplay between HCV infection
and vitamin D metabolism, as well as additional clinical data
from large and well deﬁned patient cohorts are required.s (pvt) in cirrhosis: Not only
g a pipe
temic shunt (TIPS), for complications of the resulting portal hyper-
tension [1]. We are pleased that they conﬁrmed our published
ﬁndings that TIPS is feasible and effective in patients with PVT,
including thosewithcavernous transformationof theportal vein [2].
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